As of Feb 12
| -0.06 / -1.47%|
The 4 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 11.50, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +186.78% increase from the last price of 4.01.
The current consensus among 4 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.